BPC provides in-depth market research and expert insights to keep you informed and ahead in the world of investing.
Originally listed in 2004, Somnomed (ASX: SOM) was once a rising name on the ASX. Although the company has endured a challenging period, it has regained momentum with new management implementing a strategic shift in the business that has strengthened both its financial performance and core operations.
We believe this has created a runway for the company to deliver sustained growth moving forward.
Investor Highlights
-
Proven business with proprietary solutions – First company worldwide to provide clinically proven medical oral appliance therapy to over 1 million patients in over 20 countries globally.
Turnaround in progress – Consistent double-digit revenue growth (across quarterly, annual periods over pcp) and across all global jurisdictions. New management has returned the company to cash flow positive status.
-
22% Revenue Growth YoY in FY25 to $111.5m, exceeding market guidance range of a $7m-$9m increase.
-
FY25 losses of -$0.58m, strong improvement from FY24 losses of -$13m. FY24 diluted EPS of -$0.10, improving to -$0.016 in FY25 following a pivot in operational strategy.
-
Continued penetration into global markets - Products launched further into EU territories, including national tender wins in the Nordics and the U.K. Increases in manufacturing capacity by at least 25%, set for launch in FY26 which will increase SOM’s ability to scale effectively.
Want the Full Picture?
👉 BPC is pleased to introduce our latest desk note on SomnoMed.
Gain exclusive access to in-depth analysis of SomnoMed (ASX:SOM) —valuable insights for your smarter investments. Register below to download the full report.